Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises

Minerva Neurosciences (NERV) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Minerva Neurosciences faces significant dilution risk, as over 58 million shares of common stock could be issued upon conversion of existing Series A Preferred Stock and the exercise of outstanding tranche A and B warrants. Such conversions and exercises, along with any future equity issuances, may erode existing stockholders’ ownership percentage, pressure the trading price, and reduce potential recovery in a liquidation scenario.

Overall, Wall Street has a Hold consensus rating on NERV stock based on 1 Hold.

To learn more about Minerva Neurosciences’ risk factors, click here.